LNP023
LNP023 is a pharmaceutical drug with 11 clinical trials. Currently 4 active trials ongoing. Historical success rate of 85.7%.
Success Metrics
Based on 6 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
5
Mid Stage
5
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
85.7%
6 of 7 finished
14.3%
1 ended early
4
trials recruiting
11
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients
A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in China
Clinical Trials (11)
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients
A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in China
Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316 in Patients With Paroxysmal Nocturnal Hemoglobinuria
Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy
Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment
Efficacy, Safety, Pharmacokinetics and Pharmacodynamics Study, Assessing Multiple LNP023 Doses in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria
Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted
Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation
All 11 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 11